Emerging cardiac therapies are catalyzed by next-gen technology and innovation.
The emerging cardiac therapies market is experiencing double-digit growth, thanks in large part to innovative product and next-generation technology, according to a report from Frost & Sullivan’s Transformational Health team. The growth is being driven by the growing adoption of minimally invasive procedures, advancements in technology, a rising aged population, and reimbursement policies that support new technology. As a result, Frost & Sullivan says Cardiac original equipment manufacturers (OEM) need to invest in product branding and procedure awareness among clinicians to leverage this trend and overcome adoption barriers.